To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Study sponsor: Vir Biotechnology, Inc. · VIR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04Estimated
Enrollment · participants645Estimated
Source updated2026-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.